Correction

Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B

George V Papatheodoridis1*, Eirini I Rigopoulou2, Margarita Papatheodoridi1, Kalliopi Zachou2, Vassilios Xourafas1, Nikolaos Gatselis2, Emilia Hadziyannis3, John Vlachogiannakos1, Spilios Manolakopoulos1,2, George N Dalekos2

1Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
2Department of Medicine and Research Laboratory of Internal Medicine, Thessaly University Medical School, Larissa, Greece
32nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece

*Corresponding author e-mail: gepapath@med.uoa.gr

The publisher would like to report errors in a recently published article [1]. The number of patients who cleared HBsAg during post-treatment follow-up has been corrected. The cumulative rate of HBsAg loss has been corrected. The number of patients (and percentage) that had detectable anti-HBs has also been corrected. The correct paragraph is as follows: ‘Of the 57 patients, 12 cleared HBsAg during post-treatment follow-up (3 between 1 and 6 months, 6 between 7 and 12 months and 3 between 13 and 18 months). Thus, the cumulative rate of HBsAg loss was 5%, 16% and 25% at 6, 12 and 18 months of post-NA(s) follow-up. HBsAg loss was confirmed in all cases at consecutive visits at least 1 month apart and none of the patients who achieved HBsAg clearance reverted to HBsAg seropositivity during follow-up. Anti-HBs have been detected so far in 9 (75%) of the 12 patients with HBsAg loss’. This has been corrected as of 9 August 2018. The authors apologize for these errors.

References